What smart money is saying about LENSAR, Inc.
LNSR
No fund has written a full thesis on LENSAR, Inc. in our archive, but 2 fund letters report a position in it — most recently Cedar Grove Capital Management Multi-Strategy Composite in September 2026.
Get an email when a fund writes about it
2
Reported positions
1
Bought
0
Sold
2
Letters
Position history
Between Q2 2026 and Q3 2026, 2 fund letters reported a position in LENSAR, Inc. — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 1 | 0 | 0 |
| Q2 2026 | 1 | 0 | 0 | 0 |
Fund activity · 2 positions · 1 move
- September 2026
“During the quarter, we increased our positions in Abivax (ABVX), Evolv Technologies (EVLV), Tantalus System Holding (GRID.TO), Hims and Hers Health (HIMS), Kits Eyecare (KITS.TO), LENSAR (LNSR), Nektar Therapeutics (NKTR), Hydreight Technologies (NURS.V), The RealReal (REAL), and Starling Oncology (STLN), formerly known as The Oncology Institute (TOI).”
LENSAR, Inc. - June 2026
“Investments in health care, specifically LENSAR, Grifols, and Prestige Consumer Health, also declined.”
LENSAR, Inc.
Read the letters behind these LENSAR, Inc. positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger